Cargando…

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women. Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women. Intensiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulligan, Nikki, Schalkwijk, Stein, Best, Brookie M., Colbers, Angela, Wang, Jiajia, Capparelli, Edmund V., Moltó, José, Stek, Alice M., Taylor, Graham, Smith, Elizabeth, Hidalgo Tenorio, Carmen, Chakhtoura, Nahida, van Kasteren, Marjo, Fletcher, Courtney V., Mirochnick, Mark, Burger, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972814/ https://www.ncbi.nlm.nih.gov/pubmed/27540363 http://dx.doi.org/10.3389/fphar.2016.00239

Ejemplares similares

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
por: Schalkwijk, Stein, et al.
Publicado: (2018)

Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus
por: Colbers, Angela, et al.
Publicado: (2019)

Physiologically‐based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID‐19
por: Liu, Xiaomei I., et al.
Publicado: (2022)

Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement
por: Eke, Ahizechukwu C., et al.
Publicado: (2020)

Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV
por: Eke, Ahizechukwu C., et al.
Publicado: (2020)

Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development
por: Zhao, Sherry, et al.
Publicado: (2021)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
por: Osterholzer, Danielle
Publicado: (2013)

Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
por: Agneskog, Eva, et al.
Publicado: (2014)

Experimental data of co-crystals of Etravirine and L-tartaric acid
por: Rekdal, Mikal, et al.
Publicado: (2017)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults
por: Hanan, Nathan John, et al.
Publicado: (2019)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network
por: Gebo, Kelly, et al.
Publicado: (2013)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
por: Bukkems, Vera E., et al.
Publicado: (2020)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection
por: Stellbrink, Hans-Jürgen
Publicado: (2010)

Development of a practical synthesis of etravirine via a microwave-promoted amination
por: Feng, Da, et al.
Publicado: (2018)

Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening
por: Córdova-Bahena, Luis, et al.
Publicado: (2021)

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
por: Viani, Rolando M
Publicado: (2010)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism
por: Belkhir, Leïla, et al.
Publicado: (2016)

Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically‐Based Pharmacokinetic Modeling
por: Freriksen, Jolien J.M., et al.
Publicado: (2020)

Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study
por: Echeverría, Patricia, et al.
Publicado: (2014)

Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling
por: Schalkwijk, Stein, et al.
Publicado: (2017)

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps
por: van der Galiën, Ruben, et al.
Publicado: (2018)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
por: Nelson, Mark, et al.
Publicado: (2014)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance
por: Bañón, Sara, et al.
Publicado: (2014)

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand
por: Lyons, Alex, et al.
Publicado: (2022)

Obstetric Pharmacokinetic Dosing Studies are Urgently Needed
por: McCormack, Shelley A., et al.
Publicado: (2014)

Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network
por: Bukkems, Vera, et al.
Publicado: (2020)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
por: MacBrayne, Christine E., et al.
Publicado: (2021)

Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum
por: Bustinduy, Amaya L., et al.
Publicado: (2020)

Intake of Raw Fruits and Vegetables Is Associated With Better Mental Health Than Intake of Processed Fruits and Vegetables
por: Brookie, Kate L., et al.
Publicado: (2018)

Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial
por: Frenkel, Lisa M., et al.
Publicado: (2021)

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
por: Stellbrink, HJ, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_liqpbj1g0kno18m0paua9n3i1k